Neuronetics, Inc. is a privately-held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using Transcranial Magnetic Stimulation or TMS.

The company is the leader in the commercialization of TMS therapy for Major Depressive Disorder. Since its U.S. FDA clearance in 2008, NeuroStar TMS Therapy has been administered to over 8,000 patients through more than 250,000 treatments at 425 centers in the U.S.